Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

PathAI Announces Research Presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions with end-to-end central pathology and histology services, today announced it will present research underscoring the efficacy of PathExplore’s human interpretable features (HIFs) through three poster presentations at the Society for Immunotherapy of Cancer’s 38 th Annual Meeting on November 1-5 in San Diego, CA. The posters showcase how PathExplore provides high-resolution characterization of the tumor microenvironment (TME) through a standardized panel of HIFs derived from H&E whole slide images across multiple cancer types. Additionally, Incendia Therapeutics will present two posters reporting results that were generated utilizing PathExplore. “Building upon past publications and presentations, we continue to see the utility for histological features of the tumor microenvironment to further our understanding of disease biology, patient prognosis, and therapeutic response, which ultimately may lead to the discovery and implementation of novel biomarkers to advance precision medicine,” explained Mike Montalto, Ph.D., Chief Scientific Officer, PathAI. All three posters demonstrate the correlation between specific HIFs and established molecular measurements of the TME (e.g., gene expression profiles of specific cell populations), as well as specific HIFs and complex molecular signatures (e.g., immune phenotypes) which could better aid in the identification of patients eligible for targeted therapies, or result in the identification of new histology-based biomarkers. Quantifying the effect of microsatellite instability and mismatch repair deficiency on the tumor microenvironment (Poster 73) In this research, PathAI investigated the potential to predict and compare microsatellite stability and mismatch repair subtypes in colorectal and endometrial cancers utilizing PathExplore HIFs. The findings suggest MSS/dMMR tumors may warrant consideration for immunotherapy due to their TME’s similarity to microsatellite instability-high (MSI-H) and tumor mutation burden-high (TMB-H) solid tumors and AI-powered analysis of H&E WSI presents a more accessible and scalable method than current dMMR testing options. This poster will be presented by Judy Chen and Shima Nofallah on Friday, November 3 rd. Poster hall hours are 9 a.m. to 7 p.m. PT. Quantification of tumor infiltrating lymphocytes (TILs) from pathology slides reflects molecular immune phenotypes (Poster 122) In this research, PathAI deployed its PathExplore products on H&E WSI across eight cancer indications to extract HIFs quantifying the TME, including features that represent TIL fractions, densities, and distributions. Analysis revealed statistically significant correlations between TIL-associated HIFs with gene expression of known lymphocyte markers, as well as immune signature scores such as lymphocyte infiltration. These results show the predictive power that TIL-associated HIFs have for identifying immune phenotypes, as well as a promising direction for the discovery of histology-based immune biomarkers. This poster will be presented by Judy Shen on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Deep learning models identify key tumor microenvironment features associated with genetic signatures of UV metagenesis and alkylating agent treatment in melanoma (Poster 110) In this research, PathAI used PathExplore HIFs to investigate the association between TME features and mutational signatures indicative of UV mutagenesis, as well as alkylating agents-induced mutations. The results suggest that quantifying a tumor’s tissue and cellular composition can reveal meaningful information regarding the underlying mutation-driven or treatment-induced changes in the TME, which may have implications for therapy selection. This poster will be presented by Shima Nofallah on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Incendia Therapeutics (formerly known as Parthenon Therapeutics) posters In addition to the posters above, Incendia Therapeutics will present two posters on Friday, November 3 rd reporting results that were generated utilizing PathExplore. One poster (Poster 1287) compares PathExplore HIFs to mIF features and concluded that "TME models are a robust tool to distinguish tissue and cell features from H&E slides, comparable to mlF image analysis, but requiring less effort, time, and expense." In the second (Poster 1497), Incendia Therapeutics leveraged HIFs quantifying lymphocyte densities across cancer epithelium, cancer stroma, and the epithelial-stromal interface (ESI) to characterize barriers to lymphocyte entry into the cancer epithelium across immune phenotypes. More information on these posters can be found at https://www.incendiatx.com Please visit the PathAI booth, 615, to learn more and meet the team, or email us at bd@pathai.com. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 31, 2023 10:00 AM Eastern Daylight Time

How Rexis Biotech Aims To Become The Nvidia Of The Consumer Products Industry

Rexis Biotech

By Meg Flippin, Benzinga Click here to learn more about Rexis Systems’ crowdfunding raise, and how to invest Cannabis is going mainstream as more states legalize the leafy herb. That's spawning a multi-billion-dollar market for CBD and THC products, with manufacturers putting it in everything from candy to drinks. The cannabis-infused beverage category in particular is growing in popularity as people look for healthier ways to get a buzz. Last year, the cannabis drink market was valued at $0.4 billion. By 2032, it is projected to reach $8.3 billion at a 37.7% CAGR over 2023-2032. These drinks promise to give consumers a smoother, gentler taste with few calories and zero hangover in the morning. Rexis Biotech Inc., the biotech out of Delaware, is taking the cannabis-infused beverage market to the next level with its proprietary Fused Polymorph Nano Fiber Technology™ that enhances the benefits and effects of cannabis in drinks. The current cannabis-infused drinks on the market do provide a new experience to consumers, but there are some limitations. For starters, the body can’t efficiently absorb most plant-based ingredients like CBD, THC and caffeine. As a result, consumers typically only receive 10% or less of the ingredient in their system. It also takes longer to absorb into the bloodstream, usually 45 to 90 minutes, when using oil-based infusions. These tend to give more of an edible high, as they are processed during first-pass digestion, versus the smoking high that using nanotechnology is supposed to create. Up until now, nanoemulsions have been the go-to solution to solve for faster onset, but emulsions tend to be unstable, easily losing 30% efficacy within the first three months. On top of that, they often leave a bitter or oily aftertaste in your mouth. Rexis Enhances The Benefits Rexis Biotech reports that its proprietary drug delivery platform eliminates those undesirable aspects of nanoemulsions, allowing them to create a lineup of Hemp Delta-9 THC-infused beverages that both taste amazing and enhance the consumer experience. Squared, the first beverage out of the gate for Rexis, is a lineup of better-for-you-sodas that are both delicious and nutritious. Available in a variety of flavors from their Classic Orange Pop that tastes exactly like an Orange Crush to their High Spirits Awards-winning Sparkling Grapefruit, these cannabis-infused beverages onset in about 10-15 minutes and provide a reliable effect that’s closer to the dosage on the can. Rexis says it is able to achieve that thanks to its fast-acting nano fiber technology which enables the drink to quickly absorb through the buccal membranes in the mouth versus having to go through first-pass digestion like traditional edibles. This allows the body to absorb and process the Hemp Delta-9 THC faster and more effectively. Squared beverages are also formulated to offset in about an hour – a key differentiator. It puts consumers in the driver’s seat regarding how much and how long they want to feel the effects. Squared Is Just The Beginning Rexis is demonstrating its nanotechnology with the launch of Squared, but its vision is much bigger. It wants to share its technology, aiming to be the Nvidia Corp. (NASDAQ: NVDA) or Intel Corp. (NASDAQ: INTC) of the consumer products industry. It envisions a world where brands license Rexis’s nanotechnology to enhance everything from drinks to food. Its partnership with 3Chi, Inc., one of the world’s largest hemp-derived consumer packaged goods manufacturers and retailers, underscores how it’s making that ambition a reality. Functional foods and beverages “Powered by Rexis” will be sold via their national distribution network, Wicked Smart Food Company, and they expect it to drive revenues of $24.6 million over the next three years. “Rexis separates itself from the competition with its technology. Their Fused Polymorph Nano Fiber is several steps above anything else that's in the marketplace right now. The quality of product that we have gotten from them is unsurpassed,” Justin Journay, 3Chi CEO, said when the deal was announced in July. The cannabis-infused beverage market seems to be taking off, and Rexis wants to be a leader. As more states legalize it and consumers clamor for healthier and tastier alternatives, Rexis is betting its proprietary nanotechnology will become the engine that drives these beverages like Intel’s chips power PCs. Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in the Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Ryan Erving ryan@rexissystems.com Company Website https://www.rexissystems.com

October 31, 2023 09:15 AM Eastern Daylight Time

Groundwork BioAg Supercharges Agricultural Carbon Sequestration

Groundwork BioAg

Groundwork BioAg ® announced today the global launch of the Rootella Carbon ™ program, based on mycorrhizal carbon - a frontier technology that leverages mycorrhizal fungi as a nature-based solution for carbon dioxide removal. Rootella Carbon harnesses the power of Rootella® – highly effective mycorrhizal inoculants that are proven to sequester significant amounts of carbon in cropland (1-4 tCO2eq/acre annually). This innovative, Verra-certified program represents a transformative approach to carbon sequestration for conventional and regenerative farmers alike. “Since our inception, we have known that mycorrhiza – the Queen of Biologicals™ – offers a compelling agricultural solution to mitigate climate change,” said Dr. Yossi Koffman, co-founder and CEO of Groundwork BioAg. “Rootella Carbon delivers on that vision by paving the way to a gigaton of CO2 sequestration in the next decade.” Rootella has been applied on over 4.5 million acres in 17 countries. Rootella Carbon Enrollment Unlocks New Value Carbon credit programs have been touted as a new revenue source for farmers, but adoption has been slow thus far due to high costs and practice change requirements. In a recent survey of top producers in the United States, 63% of respondents said they would enroll in a carbon program if a product like Rootella unlocks additional revenue and fits easily into existing farming practices. Simultaneously, carbon buyers are fueling demand for premium, verifiable credits to meet net-zero pledges responsibly and sustainably. This year, a select group of corn, soybean, alfalfa, and cotton farmers across eight states enrolled acres in Rootella Carbon, the first mycorrhizal carbon project in the world. “Clearly soil biology is the new frontier and will be for the next 10 years,” said Sledge Taylor, who farms corn, soybean and cotton on a multi-generational farm in Mississippi and enrolled in Rootella Carbon. "I invest in my soil; it is a true asset." Rootella Carbon Program Ushers in a New Asset Class • Enables Adoption by Conventional and Regenerative Farmers: Rootella Carbon provides growers the additionality, or practice change, needed for carbon credit eligibility, regardless of current cultivation practices. • Delivers Carbon Permanence: Mycorrhizal fungi are carbon’s main pathway into the soil. Up to 20% of plant photosynthate is passed to mycorrhizae, creating a positive net flux of carbon into the soil. Mycorrhizae aggregate soil particles to form stable and recalcitrant carbon-based molecules that persist in the soil for millennia. • Boasts Impressive Co-Benefits: Groundwork BioAg was the first to crack the code on mass production of mycorrhiza for mainstream agriculture. By joining the Rootella Carbon program, farmers can leverage the co-benefits of Rootella products, including increased yields, fertilizer savings, and stress tolerance, while earning carbon credits. • Generates Premium Carbon Credits: Rootella Carbon farmers expect to sequester 1-4 tCO2eq per acre per year—an unprecedented carbon sequestration rate. Carbon buyers gain access to high-integrity, high-volume, Verra-certified carbon credits. Enrollment in Rootella Carbon is currently open to farms with a minimum of 250 acres, at https://www.groundworkbioag.com/rootella-carbon About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg’s unique and proprietary manufacturing process was the first to solve challenges inherent in high-volume, supremely concentrated mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

October 31, 2023 08:30 AM Eastern Daylight Time

Image

Evgen Pharma "delighted" with cash position after promising first half

Evgen Pharma PLC

Evgen Pharma PLC (AIM:EVG) CEO Dr Huw Jones and new CFO Toni Hanninen speak to Thomas Warner from Proactive after the clinical stage drug development company announced its interim results for the six months to 31 September 2023. Dr Jones gives an overview of how Evgen has been performing on the operational side, highlighting clinical progress, the successful receipt of some new grant funding as well as changes to the board and to the executive team with the hiring of Toni Hanninen in late summer. Hanninen gives an overview of how Evgen performed financial during the reporting period, noting that there were no nasty surprises during the six months and that the company's cash runway of £3.7mln currently runs to the end of 2024. He goes on to say that he is "very very delighted" with the length of the runway given the financial challenges many of Evgen's peers are currently facing. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 31, 2023 06:43 AM Eastern Daylight Time

Video

News Release

Medicus Pharma CEO rings opening bell at the Toronto Stock Exchange

Medicus Pharma

Medicus Pharma executive chairman and CEO Dr Raza Bokhari joined Steve Darling from Proactive fresh from ringing the opening bell at the Toronto Stock Exchange. This after the company recently listed its common shares on the TSX Venture exchange under the ticker MDCX. Medicus Pharma is dedicated to accelerating novel life sciences and biotechnology companies by advancing them through FDA-approved clinical trials. The company specializes in de-risking clinical-stage assets through clinical development and eventual commercialization. Medicus Pharma has a subsidiary called Skinject, which is focused on commercializing a novel, non-invasive treatment for basal cell and squamous cell skin cancer. Skinject employs a patented dissolvable microneedle patch to deliver a chemotherapeutic agent that targets and eradicates tumor cells effectively. The company recently welcomed Dr Huma Qamar as its chief scientific officer and head of R&D Program. Dr Qamar brings a wealth of experience in the clinical research field, having worked with prestigious institutions such as Yale University, Harvard University, and the University of Pennsylvania. Medicus Pharma's listing on the TSX Venture Exchange represents a significant step forward for the company as it continues its mission to advance innovative therapies and treatments in the field of life sciences and biotechnology. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:31 PM Eastern Daylight Time

Video

News Release

Marizyme Inc CEO releases corporate update including details of key progress on DuraGraft

Marizyme Inc

Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for its groundbreaking product, DuraGraft. DuraGraft is a first-in-class vascular conduit solution that has received FDA clearance, marking a significant milestone for Marizyme. This innovative product is specifically indicated for use in adult patients undergoing Coronary Artery Bypass Grafting (CABG) surgeries. Its primary purpose is to facilitate the flushing and storage of saphenous vein grafts employed in CABG procedures, offering a cutting-edge solution to enhance patient outcomes in cardiac surgery. One notable aspect of Marizyme's progress is the growing acceptance of DuraGraft in both Europe and Asia. The company has achieved impressive sales figures, with a total of 1,131 DuraGraft kits shipped so far this year. This is a remarkable increase compared to the 485 DuraGraft kits shipped in the previous year, underscoring the product's traction and demand in the international market. In summary, Marizyme, under the leadership of CEO David Barthel, is making significant strides in the medical industry. The FDA approval of DuraGraft and its increasing adoption in international markets signify the company's commitment to advancing medical technologies that improve patient outcomes. As Marizyme continues to expand its reach and forge new partnerships, it is poised for continued growth and success in the years ahead. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:23 PM Eastern Daylight Time

Video

News Release

BioHarvest Sciences closes first tranche of financing bringing in C$11.78M to Treasury

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share some exciting developments. The company has achieved a major milestone by successfully closing the first tranche of its financing, raising nearly C$12 million, even in the face of challenging market conditions. This accomplishment underscores the significant investor confidence in BioHarvest's strategic vision and the strength of its management team. The capital raised through this financing round will play a pivotal role in advancing several key initiatives within BioHarvest Sciences. One of the notable areas of focus is new product development and expansion. BioHarvest has ambitious plans to expand its product range, moving from a single SKU to ten SKUs spanning five different categories. Leveraging its advanced scientific capabilities, proven efficacy, and exceptional taste, the company is poised to make a significant impact in these markets. The eagerly awaited flagship product, a revolutionary coffee offering, is slated to disrupt the market starting in December. Geographical expansion is another crucial aspect of BioHarvest's growth strategy. With recent approval from Health Canada, the company is gearing up to enter the Canadian market, further extending its global footprint. Additionally, BioHarvest is accelerating clinical trials across various domains, positioning itself for substantial growth over the next 12 to 24 months. These clinical trials will not only underscore the efficacy of their products but also enhance their credibility and market presence. Despite the challenges posed by the current market conditions, BioHarvest remains unwavering in its commitment to the safety of its employees and the consistent delivery of high-quality products. The company's focus for the remainder of 2023 includes robust marketing initiatives and the highly anticipated launch of its innovative coffee product, aimed at revitalizing the stagnant decaffeinated coffee market. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:18 PM Eastern Daylight Time

Video

News Release

1606 Corp announces cutting-edge AI-driven ChatCBDW will launch on Tuesday

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to unveil some thrilling news: the impending launch of its cutting-edge AI chatbot, ChatCBDW. With ChatCBDW currently undergoing final testing phases, the countdown to its official launch is well underway. Lambrecht eagerly shared with Proactive the multifaceted capabilities that ChatCBDW is poised to bring to its users. This AI chatbot has been meticulously designed to offer a diverse range of user-centric features that go beyond the ordinary. Among its standout attributes are its ability to respond to user queries and provide comprehensive education on all aspects of CBD. But ChatCBDW doesn't stop there; it takes personalization to the next level by offering tailored product recommendations to users and engaging in conversations that closely mimic human interaction. This innovation empowers customers to make well-informed choices, explore a wide array of CBD products, and promises an unparalleled shopping experience in the CBD space. At the core of ChatCBDW's prowess is its seamless integration with Microsoft Azure, a platform renowned for its scalability, unwavering reliability, and cutting-edge AI functionalities. This integration ensures that ChatCBDW can operate impeccably, even during peak demand periods, guaranteeing users a consistently responsive and seamless experience throughout their interaction with the chatbot. Notably, 1606 Corp proudly retains 100% ownership of ChatCBDW's intellectual property, demonstrating its commitment to maintaining control over this groundbreaking technology. This ownership provides the company with the flexibility to continually enhance and adapt ChatCBDW to meet the ever-evolving needs of its users and partners across various industries. It signifies 1606 Corp's dedication to staying at the forefront of innovation in the field of AI-driven customer engagement and CBD product discovery. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 02:16 PM Eastern Daylight Time

Video

News Release

BioVie CEO reveals stunning results in Alzheimer's and Parkinson's drug trial

BioVie Inc

BioVie Inc CEO Cuong Do joined Steve Darling from Proactive to share news the company will be presenting its blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer’s Disease. The presentation will be presented at the upcoming 16th Clinical Trials on Alzheimer's Disease in Boston. Do told Proactive the company has monitored blinded data as they become available throughout the trial to assess patient safety and support timely data entry into the official statistical analysis database. Interim blinded data was previously presented at other scientific congresses to provide a glimpse of the characteristics of the enrolled subjects at the start of the trial. The most surprising revelation was the reduction in amyloid burden. NE3107, designed to block TNF alpha, demonstrated a substantial reduction in amyloid buildup within just six months of treatment. More than a third of initially amyloid-positive patients became amyloid-negative, a highly unexpected outcome. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

October 30, 2023 01:00 PM Eastern Daylight Time

Video

1 ... 65 66 67 68 69 ... 249